Kamunting Street Capital Management’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Kamunting Street Capital Management’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-137,549	Closed	-$99K	–	38
2022 Q3	$99K	Hold	137,549	–	–	0.16%	29
2022 Q2	$73K	Hold	137,549	–	–	0.1%	33
2022 Q1	$121K	Hold	137,549	–	–	0.15%	29
2021 Q4	$308K	Sell	137,549 -46,452	-25%	-$150K	0.23%	37
2021 Q3	$624K	Buy	+184,001	New	+$655K	0.28%	37

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

JFGLC

Johnson Financial Group LLC (Colorado) Denver, Colorado $1.86B AUM 22.33% 1-Year Est. Return

Kamunting Street Capital Management's DNA.WS Position: Q4 2022 in Review

Kamunting Street Capital Management sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2022, closing a stake of 137,549 shares — an estimated $99K sold.

Kamunting Street Capital Management first reported a position in DNA.WS in Q3 2021 and held it in 5 quarters. The position peaked at $624K in Q3 2021. 44 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2022.

Kamunting Street Capital Management reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2022 after selling out during the quarter.
Kamunting Street Capital Management sold 137,549 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2022, an estimated $99K.
Kamunting Street Capital Management first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 5 quarters.
Kamunting Street Capital Management's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $624K in Q3 2021.
44 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2022.

Based on Kamunting Street Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.